Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

doi:10.7554/eLife.54493

. 2020 May 13:9:e54493.

doi: 10.7554/eLife.54493.

Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

Maria-Bernadette Madel^{1

2}, Lidia Ibáñez³, Thomas Ciucci⁴, Julia Halper^{1

2}, Matthieu Rouleau^{1

2}, Antoine Boutin^{1

2}, Christophe Hue⁵, Isabelle Duroux-Richard⁶, Florence Apparailly⁶, Henri-Jean Garchon^{5

7}, Abdelilah Wakkach^{1

2}, Claudine Blin-Wakkach^{1

2}

Affiliations

¹ Laboratoire de PhysioMédecine Moléculaire, CNRS, Nice, France.
² Université Côte d'Azur, Nice, France.
³ Department of Pharmacy, Cardenal Herrera-CEU University, Valencia, Spain.
⁴ Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States.
⁵ Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny-Le-Bretonneux, France.
⁶ IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
⁷ Genetics division, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.

PMID: 32400390
PMCID: PMC7220377
DOI: 10.7554/eLife.54493

Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

Maria-Bernadette Madel et al. Elife. 2020.

. 2020 May 13:9:e54493.

doi: 10.7554/eLife.54493.

Authors

Affiliations

¹ Laboratoire de PhysioMédecine Moléculaire, CNRS, Nice, France.
² Université Côte d'Azur, Nice, France.
³ Department of Pharmacy, Cardenal Herrera-CEU University, Valencia, Spain.
⁴ Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States.
⁵ Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny-Le-Bretonneux, France.
⁶ IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France.
⁷ Genetics division, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France.

PMID: 32400390
PMCID: PMC7220377
DOI: 10.7554/eLife.54493

Abstract

Bone destruction relies on interactions between bone and immune cells. Bone-resorbing osteoclasts (OCLs) were recently identified as innate immune cells activating T cells toward tolerance or inflammation. Thus, pathological bone destruction not only relies on increased osteoclast differentiation, but also on the presence of inflammatory OCLs (i-OCLs), part of which express Cx3cr1. Here, we investigated the contribution of mouse Cx3cr1⁺ and Cx3cr1^neg i-OCLs to bone loss. We showed that Cx3cr1⁺ and Cx3cr1^neg i-OCLs differ considerably in transcriptional and functional aspects. Cx3cr1^neg i-OCLs have a high ability to resorb bone and activate inflammatory CD4⁺ T cells. Although Cx3cr1⁺ i-OCLs are associated with inflammation, they resorb less and have in vitro an immune-suppressive effect on Cx3cr1^neg i-OCLs, mediated by PD-L1. Our results provide new insights into i-OCL heterogeneity. They also reveal that different i-OCL subsets may interact to regulate inflammation. This contributes to a better understanding and prevention of inflammatory bone destruction.

Keywords: bone destruction; cell biology; immunology; inflammation; mouse; osteoclast; osteoimmunology; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

MM, LI, TC, JH, MR, AB, CH, ID, FA, HG, AW, CB No competing interests declared

Figures

**Figure 1.. *Cx3cr1*-deficient mice display reduced bone loss after ovariectomy.**
(A) FACS analysis of Cx3cr1⁺ OCLs generated from BM cells from SHAM-operated and OVX WT mice. Histograms indicate the mean ± SD percentage of Cx3cr1⁺ i-OCLs (n = 4–5). (B) Representative images of femur µCT analysis from SHAM-operated and OVX WT *Cx3cr1*^GFP/+ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP mice 6 weeks post-surgery. (C) Histograms show the mean ± SD percentage of bone volume fraction (BV/TV), trabecular number and trabecular separation (n = 8 mice per group). (D) Representative TRAcP staining on femora from OVX Cx3cr1^GFP/+ and Cx3cr1^GFP/GFP mice. Scale bar = 100 µm. (E) Ex vivo FACS analysis of CD11c⁺ DCs and (F) CD11b⁺Ly6C^hi MNs present in the BM of SHAM and OVX mice. Cells were gated as in Figure 1—figure supplement 2 and histograms are showing the absolute cell number of these populations in the bone marrow. **p<0.01; ***p<0.001; n.s., no significant difference.

**Figure 1—figure supplement 2.. Gating strategy for ex vivo FACS analysis.**
Gating strategy for ex vivo FACS analysis of bone marrow DCs and inflammatory monocytes in SHAM and OVX mice.

**Figure 2.. Cx3cr1 deficiency does not affect resorption and immune function in Cx3cr1⁺ i-OCLs.**
(A) Schematic representation of the differentiation of i-OCLs from BM-derived DCs of WT *Cx3cr1*^GFP/+ and Cx3cr-deficient *Cx3cr1*^GFP/GFP mice. (B) RNA-seq analysis on sorted GFP⁺ i-OCLs (representing Cx3cr1⁺ i-OCLs) differentiated from BM-derived DCs of WT *Cx3cr1*^GFP/+ and Cx3cr-1deficient *Cx3cr1*^GFP/GFP mice (gated as in Figure 2—figure supplement 1). Volcano-plot indicates –Log₁₀ adjusted p value versus log₂fold-change comparing gene expression in i-OCL subsets. (C) Matrix dissolution activity of sorted GFP⁺ i-OCLs from WT *Cx3cr1*^GFP/+ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP mice seeded at the same cell density on a calcified matrix was evidence by red alizarin staining of the mineralized matrix. Unstained areas correspond to the resorbed areas. Left panel: representative images of resorbed area. Scale bar = 100 µm. Right panel: quantification of resorbed areas presented as mean ± SD percentage of three independent biological replicates each in triplicates. (D) FACS analysis of fluorescent-OVA uptake among GFP⁺ i-OCLs from *Cx3cr1*^GFP/+ and *Cx3cr1*^GFP/GFP mice. Left panel: representative density plots and right panel: percentage of OVA⁺ cells from five independent experiments. (E) FACS analysis of GFP⁺ i-OCLs from *Cx3cr1*^GFP/+ and *Cx3cr1*^GFP/GFP mice in at least four independent experiments. (F) T cell proliferation assay on CD4⁺ T cells labelled with CFSE and cultured in the presence of OVA-challenged GFP⁺ i-OCLs differentiated from *Cx3cr1*^GFP/+ and *Cx3cr1*^GFP/GFP mice and analyzed by FACS after 4 days of coculture. (G) CD4⁺ T cells activated by OVA-challenged GFP⁺ i-OCLs from *Cx3cr1*^GFP/+ and *Cx3cr1*^GFP/GFP mice were analyzed for their expression of TNFα and IFNγ by FACS after intracytoplasmic staining of these cytokines. n.s., no significant difference.

**Figure 2—figure supplement 1.. Gating strategy for mature Cx3cr1⁺ and Cx3cr1^neg i-OCLs.**
(A) Gating strategy for the analysis and sorting of mature GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs using flow cytometry. After gating on total cells, doublets were excluded and cells with ≥3 nuclei (≥3N) cells were considered as OCLs and distinguished from 1 to 2 nucleated (1–2N) cells based on their Hoechst 33342 staining level. OCLs were analyzed based on their GFP expression and GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs were sorted.

**Figure 2—figure supplement 2.. Comparative transcriptomic analysis of Cx3cr1⁺ i-OCLs from *Cx3cr1*^GFP/GFP and *Cx3cr1*^GFP/+ mice.**
(A) Comparative RNA-seq analysis between GFP⁺ (Cx3cr1⁺) i-OCLs from KO *Cx3cr1*^GFP/GFP and WT *Cx3cr1*^GFP/+ mice. Heatmap visualization of the z-scored expression for selected genes involved in OCL differentiation, T cell stimulation and antigen presentation. (B) Relative mRNA expression of GFP⁺ (Cx3cr1⁺) i-OCLs from KO *Cx3cr1*^GFP/GFP and WT *Cx3cr1*^GFP/+ mice. Results are represented as the mean with 95% confidence interval of three independent biological replicates conducted in triplicates. n.s., no significant difference.

**Figure 3.. Transcriptomic profiling of Cx3cr1⁺ and Cx3cr1^neg i-OCLs reveals two distinct populations of i-OCLs.**
(A) Schematic representation of the differentiation of GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs from BM-derived DCs of WT *Cx3cr1*^GFP/+ mice and their sorting (gated as in Figure 2—figure supplement 1). (B) Principal component analysis of Cx3cr1⁺ and Cx3cr1^neg i-OCLs clusters samples in two groups (red: GFP⁺ (Cx3cr1⁺) OCLs and blue GFP^neg (Cx3cr1^neg) OCLs, both from *Cx3cr1*^GFP/+ mice). Data shows the two first components on the top 500 most differentially expressed genes after batch correction. Each dot represents the expression profile of one sample. (C) Volcano-plot showing representative differentially expressed genes for Cx3cr1⁺ and Cx3cr1^neg i-OCLs. Cut-off values were defined by a fold change (FC) >2 and an adjusted p-value<0.05. (D) Heatmap visualization of the top 107 genes significantly differentially expressed between GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs from *Cx3cr1*^GFP/+ mice (adjusted p-value<0.05, FC ≥2). (E) Graphical representation of gene ontology analysis associated with differentially expressed genes between Cx3cr1⁺ and Cx3cr1^neg i-OCLs.

**Figure 3—figure supplement 1.. Cx3cr1⁺ and Cx3cr1^neg i-OCLs differ in their expression of Cx3cr1-interacting genes.**
(A) Heatmap visualization of selected genes involved in the Cx3cr1 pathway that are significantly differentially expressed (p<0.05, FC ≥2) between GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs differentiated from WT *Cx3cr1*^GFP/+ mice. (B) Relative expression levels of *Nr1d1* and (C) *Tlr4* in Cx3cr1⁺ and Cx3cr1^neg i-OCLs. (D) BM-derived DCs from *Cx3cr1*^GFP/+ mice were sorted based on their expression of GFP and were differentiated into i-OCLs. Both GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) DCs gave rise to approx. 20% of Cx3cr1⁺ i-OCLs. *p<0.05; ****p<0.0001.

**Figure 4.. Cx3cr1^neg and Cx3cr1⁺ i-OCLs differ in their resorbing activity.**
(A) Heatmap visualization of the z-scored expression for selected genes involved in bone resorption, osteoclast fusion and differentiation that are differentially expressed between GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs both differentiated from WT *Cx3cr1*^GFP/+ mice (adjusted p-value<0.05, FC ≥2). (B) RT-qPCR analysis on GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs. Results are represented as the mean with 95% confidence interval of 3 independent biological replicates in triplicates. (C) Flow cytometry analysis of TRAcP expression using ELF95 substrate in the 2 i-OCLs subsets. Percentage of positive cells (dark curve) compared to the negative control (light curve) is indicated. (D) Quantification of the mean fluorescence intensity (MFI) of TRAcP in GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs (n = 3). (E) Representative images of matrix dissolution activity of sorted GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs seeded at the same cell density. Red alizarin staining of the mineralized matrix revealed the resorbed areas as unstained. Scale bar = 100 µm. (F) Quantification of resorbed areas from three independent experiments in triplicates are indicated as percentage. ****p<0.0001; n.s., no significant difference.

**Figure 4—figure supplement 1.. Cx3cr1⁺ i-OCLs differ from Cx3cr1⁺ BM-derived macrophages.**
(A) Schematic representation of the differentiation of macrophages from the BM of *Cx3cr1*^GFP/+ mice. (B) FACS analysis of macrophage markers on BM-derived macrophages and (C) on GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs (n = 3). (D) Quantification of CD68⁺CD169⁺ cells in Cx3cr1⁺ BM-derived macrophages and in Cx3cr1^neg and Cx3cr1⁺ i-OCL subsets. (E) Representative images of TRAcP staining on i-OCLs and BM-derived macrophages showing that contrasting to i-OCLs that all express TRAcP, BM-derived macrophages are negative for TRAcP expression. Scale bar = 50 µm.

**Figure 5.. Cx3cr1^neg and Cx3cr1⁺ subsets differ in their antigen uptake and presentation.**
(A) Heatmap visualization of the z-scored expression for selected genes involved in antigen uptake, processing and presentation that are differentially expressed between GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs from WT *Cx3cr1*^GFP/+ mice (adjusted pVal <0.05, FC ≥2). (B) Representative FACS plots of OVA uptake in Cx3cr1⁺ and Cx3cr1^neg i-OCLs. (C) Quantification of FACS analysis for OVA uptake in GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs (n = 5). (**D–F**) FACS analysis of GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs for (D) MHC-II, (E) CD80 and (F) CD86 (n = 6). (G). Representative FACS histograms for T cell proliferation assay of CFSE-labelled CD4⁺ T cells from OT-II mice cultured with OVA-loaded GFP⁺ (Cx3cr1⁺) or GFP ^neg (Cx3cr1^neg) i-OCLs after 5 days of coculture. **p<0.01; n.s., no significant difference.

Figure 5—figure supplement 1.. CD4⁺ T cell polarization analysis CD4⁺ T cells from OT-II mice were cocultured with OVA-challenged GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs from WT *Cx3cr1*^GFP/+ mice, respectively, and analyzed by intracytoplasmic staining for their (A) TNFα, (B) IFNγ and (C) FoxP3 expression using flow cytometry. n.s., no significant difference.

**Figure 6.. Cx3cr1^neg and Cx3cr1⁺ subsets differ in their T cell activation capacity.**
(A) Heatmap visualization of the z-scored expression for selected genes involved in T cell stimulation and inhibition that are differentially expressed between GFP⁺ (Cx3cr1⁺) and GFP^neg (Cx3cr1^neg) i-OCLs from WT *Cx3cr1*^GFP/+ mice (adjusted p<0.05, FC ≥2). (B) RT-qPCR analysis of immunosuppressive molecules. Graphs show three independent experiments conducted in triplicates. (C) Representative FACS histograms and quantification of the proliferation of CSFE-labelled CD4⁺ T cell from OT-II mice cocultured with OVA-loaded Cx3cr1⁺ i-OCLs from WT *Cx3cr1*^GFP/+ mice and an isotype antibody (left panel) or an anti-PD-1 antibody (right panel). (D) Schematic representation of the experimental setup. Sorted GFP^neg (Cx3cr1^neg) i-OCLs from WT *Cx3cr1*^GFP/+ mice were loaded with OVA for 3 hr and incubated with CFSE⁺ CD4⁺ T cells in the presence of different rations of non-OVA loaded GFP⁺(Cx3cr1⁺) i-OCLs from WT *Cx3cr1*^GFP/+ mice. (E) FACS analysis and quantification of CFSE⁺ CD4⁺ T cells of OT-II mice cocultured in the presence of different ratios (1:0; 1:1; 1:2) between OVA-loaded Cx3cr1^neg i-OCLs and Cx3cr1⁺ i-OCLs (non-loaded with OVA) for 5 days. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; n.s., no significant difference.

**Figure 7.. Heterogeneity of osteoclasts and underlying molecular mechanisms.**
In steady state, BM progenitors differentiate into tolerogenic OCLs (t-OCLs) that are able to present antigens and induce CD4⁺ Treg cells. During inflammation, inflammatory MNs and DCs are recruited to the BM and differentiate into i-OCLs. Approx. 25% of these i-OCLs can be characterized by their expression of Cx3cr1 while the majority of i-OCLs does not express this marker. Cx3cr1^neg i-OCLs show significantly higher bone resorption activity in vitro compared to Cx3cr1⁺ i-OCLs. Both i-OCL subsets act as antigen-presenting cells but differ in their T cell activation capacity that is higher for the Cx3cr1^neg i-OCL subset. Both i-OCL subsets are able to induce TNFα-producing CD4⁺ T cells, however the Cx3cr1⁺ OCL subset express high levels of co-inhibitory molecules such as PD-L1 that reduce their capacity to activate T cells. Moreover, Cx3cr1⁺ i-OCLs have an immune suppressive effect on Cx3cr1 ^neg i-OCLs by reducing their T cell proliferation capacity in vitro.

**Author response image 1.. Cx3cr1^neg i-OCLs from Cx3cr1^GFP/+ mice are distinct from Cx3cr1⁺ i-OCLs from deficient Cx3cr1^GFP/GFP mice.**
A) Principal component analysis of Cx3cr1⁺ from deficient Cx3cr1^GFP/GFP mice (green) and Wt Cx3cr1^GFP/+ mice (red) and Cx3cr1^neg i-OCLs from Cx3cr1^GFP/+ mice (blue). Data shows the two first components after batch correction. Each dot represents the expression profile of one sample. B) Similarity matrix analysis on the same samples.

See this image and copyright information in PMC

Cited by

Novel insights into the coupling of osteoclasts and resorption to bone formation.
Durdan MM, Azaria RD, Weivoda MM. Durdan MM, et al. Semin Cell Dev Biol. 2022 Mar;123:4-13. doi: 10.1016/j.semcdb.2021.10.008. Epub 2021 Oct 30. Semin Cell Dev Biol. 2022. PMID: 34756783 Free PMC article. Review.
Interleukin-23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A(+) Osteoclast Precursors.
Furuya H, Nguyen CT, Gu R, Hsieh SL, Maverakis E, Adamopoulos IE. Furuya H, et al. Arthritis Rheumatol. 2023 Aug;75(8):1477-1489. doi: 10.1002/art.42478. Epub 2023 Jun 6. Arthritis Rheumatol. 2023. PMID: 36787107 Free PMC article.
Origin of Osteoclasts: Osteoclast Precursor Cells.
Tsai J, Kaneko K, Suh AJ, Bockman R, Park-Min KH. Tsai J, et al. J Bone Metab. 2023 May;30(2):127-140. doi: 10.11005/jbm.2023.30.2.127. Epub 2023 May 31. J Bone Metab. 2023. PMID: 37449346 Free PMC article.
The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence.
Liu Y, Chen H, Chen T, Qiu G, Han Y. Liu Y, et al. Front Oncol. 2024 Aug 1;14:1445025. doi: 10.3389/fonc.2024.1445025. eCollection 2024. Front Oncol. 2024. PMID: 39148909 Free PMC article. Review.
Inhibition of inflammatory osteoclasts accelerates callus remodeling in osteoporotic fractures by enhancing CGRP⁺TrkA⁺ signaling.
Shu Y, Tan Z, Pan Z, Chen Y, Wang J, He J, Wang J, Wang Y. Shu Y, et al. Cell Death Differ. 2024 Dec;31(12):1695-1706. doi: 10.1038/s41418-024-01368-5. Epub 2024 Sep 2. Cell Death Differ. 2024. PMID: 39223264 Free PMC article.

See all "Cited by" articles

References

1. Ammari M, Presumey J, Ponsolles C, Roussignol G, Roubert C, Escriou V, Toupet K, Mausset-Bonnefont AL, Cren M, Robin M, Georgel P, Nehmar R, Taams L, Grün J, Grützkau A, Häupl T, Pers YM, Jorgensen C, Duroux-Richard I, Courties G, Apparailly F. Delivery of miR-146a to Ly6C high monocytes inhibits pathogenic bone erosion in inflammatory arthritis. Theranostics. 2018;8:5972–5985. doi: 10.7150/thno.29313. - DOI - PMC - PubMed
1. An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016;128:1590–1603. doi: 10.1182/blood-2016-03-707547. - DOI - PMC - PubMed
1. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi: 10.1093/bioinformatics/btu638. - DOI - PMC - PubMed
1. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. The Journal of Experimental Medicine. 1999;190:1741–1754. doi: 10.1084/jem.190.12.1741. - DOI - PMC - PubMed
1. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunology and Cell Biology. 1998;76:34–40. doi: 10.1046/j.1440-1711.1998.00709.x. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Ammari M, Presumey J, Ponsolles C, Roussignol G, Roubert C, Escriou V, Toupet K, Mausset-Bonnefont AL, Cren M, Robin M, Georgel P, Nehmar R, Taams L, Grün J, Grützkau A, Häupl T, Pers YM, Jorgensen C, Duroux-Richard I, Courties G, Apparailly F. Delivery of miR-146a to Ly6C high monocytes inhibits pathogenic bone erosion in inflammatory arthritis. Theranostics. 2018;8:5972–5985. doi: 10.7150/thno.29313. - DOI - PMC - PubMed

[2] Ammari M, Presumey J, Ponsolles C, Roussignol G, Roubert C, Escriou V, Toupet K, Mausset-Bonnefont AL, Cren M, Robin M, Georgel P, Nehmar R, Taams L, Grün J, Grützkau A, Häupl T, Pers YM, Jorgensen C, Duroux-Richard I, Courties G, Apparailly F. Delivery of miR-146a to Ly6C high monocytes inhibits pathogenic bone erosion in inflammatory arthritis. Theranostics. 2018;8:5972–5985. doi: 10.7150/thno.29313. - DOI - PMC - PubMed

[3] An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016;128:1590–1603. doi: 10.1182/blood-2016-03-707547. - DOI - PMC - PubMed

[4] An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016;128:1590–1603. doi: 10.1182/blood-2016-03-707547. - DOI - PMC - PubMed

[5] Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi: 10.1093/bioinformatics/btu638. - DOI - PMC - PubMed

[6] Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–169. doi: 10.1093/bioinformatics/btu638. - DOI - PMC - PubMed

[7] Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. The Journal of Experimental Medicine. 1999;190:1741–1754. doi: 10.1084/jem.190.12.1741. - DOI - PMC - PubMed

[8] Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. The Journal of Experimental Medicine. 1999;190:1741–1754. doi: 10.1084/jem.190.12.1741. - DOI - PMC - PubMed

[9] Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunology and Cell Biology. 1998;76:34–40. doi: 10.1046/j.1440-1711.1998.00709.x. - DOI - PubMed

[10] Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunology and Cell Biology. 1998;76:34–40. doi: 10.1046/j.1440-1711.1998.00709.x. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

Affiliations

Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous